The Risperdal male breast growth gynecomastia class action represents one of the most significant pharmaceutical liability settlements involving Johnson & Johnson’s antipsychotic drug. In October 2021, J&J settled approximately 9,000 pending gynecomastia cases for $800 million, establishing average payouts of roughly $95,000 per individual claimant. This settlement capped years of litigation that began after it became clear that Risperdal, widely prescribed to millions of patients including children, could cause unexpected breast tissue growth in males—a serious and often permanent side effect that J&J had allegedly failed to adequately warn users about. The legal significance of this settlement extends beyond the monetary amount.
Austin Pledger won the first jury trial in 2015, receiving $2.5 million in damages after developing gynecomastia from Risperdal use. This verdict, along with subsequent cases, prompted J&J to negotiate the broader settlement that would resolve the bulk of pending claims. However, the settlement did not end all litigation—recent developments in 2025 and 2026 show that additional cases continue to emerge, particularly regarding failures to warn and related breast health concerns. Today, while most gynecomastia claims have been resolved through the 2021 settlement, understanding the details of this litigation remains crucial for patients who took Risperdal and experienced male breast growth. The case illustrates how pharmaceutical companies can be held accountable when they fail to adequately disclose known risks to patients and doctors.
Table of Contents
- How Did Risperdal Cause Gynecomastia and Why Was It a Hidden Risk?
- Settlement Amounts, Verdicts, and the $800 Million Agreement
- Who Qualifies for Risperdal Gynecomastia Compensation?
- How to File a Claim and Navigate the Settlement Process
- Recent Developments in Risperdal Litigation and Ongoing Cases
- Distinguishing Gynecomastia Claims from Breast Cancer Claims
- The Future of Risperdal Litigation and What Remains
- Conclusion
How Did Risperdal Cause Gynecomastia and Why Was It a Hidden Risk?
Risperdal (risperidone) is an atypical antipsychotic medication used to treat schizophrenia, bipolar disorder, and autism spectrum disorder. The drug works by affecting dopamine and serotonin receptors in the brain. However, Risperdal also has an unintended effect: it can increase prolactin levels—a hormone that stimulates breast tissue development. In males, elevated prolactin can trigger gynecomastia, the abnormal growth of breast tissue that can result in visible breast enlargement, pain, and significant psychological distress. What made this particularly problematic was the scope of Risperdal use combined with inadequate warnings.
The drug was prescribed to millions of patients, including teenagers and young men who were especially vulnerable to the psychological impact of developing female-like breast tissue. Many patients and doctors were unaware of this risk because J&J’s marketing and labeling did not adequately highlight the gynecomastia connection. In some cases, patients were told their symptoms would resolve after stopping the medication, when in fact the breast tissue growth was often permanent and required surgical intervention. The FDA eventually mandated that Risperdal’s warning labels be updated to include information about gynecomastia risk. This regulatory action came only after years of use and thousands of cases had already occurred. The delay in disclosure meant that patients who could have chosen alternative medications or been monitored more closely for symptoms instead suffered unexpected and often irreversible side effects.
Settlement Amounts, Verdicts, and the $800 Million Agreement
The pathway to the $800 million settlement involved multiple bellwether trials that established Risperdal’s liability in gynecomastia cases. Austin Pledger’s 2015 verdict of $2.5 million was groundbreaking—it was the first jury award in a Risperdal gynecomastia case and demonstrated that juries would hold J&J accountable for failing to warn about this risk. Andrew Yount achieved an even larger verdict of $70 million in 2016, though this award was later reduced through post-trial motions. These verdicts signaled to J&J that continued litigation would be expensive and unpredictable, prompting settlement negotiations. The $800 million settlement resolved approximately 9,000 pending cases, resulting in an average payout of roughly $95,000 per claimant.
However, this average masks significant variation—some claimants received more, others less, depending on factors like the severity of their gynecomastia, duration of Risperdal use, age at the time of use, and whether they underwent surgery. The settlement also included a provision that J&J would implement a claims resolution facility to process payments over time, which meant many claimants did not receive their full compensation immediately. One important limitation of the settlement is that it did not apply uniformly to all potential claimants. Some cases proceeded outside the settlement framework, and settlements varied by jurisdiction. A Montana settlement, for example, was documented at $5.9 million, indicating that regional variations and individual case circumstances continued to affect outcomes even after the broader settlement agreement.
Who Qualifies for Risperdal Gynecomastia Compensation?
To qualify for compensation under the Risperdal gynecomastia settlement or in individual cases, claimants generally needed to demonstrate several things. First, they had to show that they took Risperdal or its generic equivalent, risperidone, at some point during their treatment history. Second, they had to establish that they developed gynecomastia—either through medical documentation or credible evidence of breast tissue growth—that was temporally related to their Risperdal use. Many claimants also had to show that their gynecomastia caused them harm, which could include physical symptoms like breast tenderness or pain, or psychological harm from the appearance and social stigma.
Some cases involved claimants who underwent surgical intervention (mastectomy) to remove the breast tissue, which strengthened their claims and often resulted in larger settlements. Minors who took Risperdal were particularly strong claimants because the FDA approved Risperdal for pediatric use despite the gynecomastia risk, making children especially vulnerable. A critical consideration is that not all male breast growth qualifies as compensable gynecomastia related to Risperdal. Other conditions, medications, and medical factors can cause breast tissue growth. Claimants had to provide medical records and expert testimony linking their gynecomastia specifically to Risperdal use, which required working with experienced attorneys familiar with pharmaceutical liability litigation.
How to File a Claim and Navigate the Settlement Process
For those who took Risperdal and developed gynecomastia, the filing process typically involved several steps. First, claimants needed to contact attorneys or claims administrators who handled Risperdal cases. These legal professionals would review the claimant’s medical records, prescription history, and documentation of their gynecomastia to determine eligibility. The claims evaluation process looked at factors including when the patient took Risperdal, how long they took it, their age, and the extent of their symptoms or surgeries. One key tradeoff in settling versus continuing to litigate is time and certainty.
The settlement provided a structured process with known compensation ranges and relatively predictable timelines for payment. Individual litigation, by contrast, could result in higher awards (like the $2.5 million Pledger verdict) but involved greater legal costs, longer delays, and the risk of losing entirely. Many claimants opted for the settlement because it offered faster resolution and guaranteed compensation, even if it meant potentially receiving less than they might win at trial. The practical steps involved gathering medical records from all healthcare providers who treated the claimant during and after Risperdal use, obtaining documentation of any surgeries or medical procedures related to gynecomastia, and submitting detailed claim forms. Claimants who did not know about the settlement deadlines faced the possibility of being barred from claims if they filed too late. This made early notification and engagement with experienced Risperdal attorneys critical.
Recent Developments in Risperdal Litigation and Ongoing Cases
Despite the large 2021 settlement, litigation over Risperdal has not ended. In April 2025, lawyers filed a new lawsuit in Alameda County Superior Court alleging that Johnson & Johnson and Janssen Pharmaceuticals concealed evidence that Risperdal causes breast cancer—a distinct but related claim separate from the gynecomastia cases. This development reveals an important warning: the full scope of Risperdal’s risks to breast health may not be fully litigated even after the settlement. In November 2025, Judge Araceli Martinez-Olguin granted plaintiffs’ motion to remand Risperdal cases from federal court to Alameda County Superior Court, allowing state court litigation over failure-to-warn claims. This significant ruling suggests that additional gynecomastia and breast-related claims may continue to move forward in state courts.
By January 2026, remaining Risperdal gynecomastia claims were continuing through confidential settlements, indicating that the litigation has not completely concluded despite the 2021 agreement. A critical limitation for new claimants is timing. Many courts have imposed statutes of limitations that restrict when cases can be filed. Claimants who develop gynecomastia years after stopping Risperdal may find their claims barred by time limits, depending on their state’s laws. Additionally, the 2021 settlement agreement included provisions that could affect new claims, so claimants cannot assume they are automatically entitled to the same compensation as earlier settlement participants.
Distinguishing Gynecomastia Claims from Breast Cancer Claims
The emergence of breast cancer allegations in 2025 represents a significant escalation in Risperdal litigation. While gynecomastia involves benign (non-cancerous) breast tissue growth, breast cancer claims allege that Risperdal exposure increases the risk of malignant tumors. This distinction matters enormously for damages, medical consequences, and legal strategy. Breast cancer is life-threatening; gynecomastia, while distressing and sometimes requiring surgery, is not.
The April 2025 lawsuit alleging J&J concealed evidence of Risperdal-induced breast cancer suggests that internal company documents or research may show a connection between Risperdal and malignant breast disease that was not disclosed to patients or regulators. If these claims succeed, they could open an entirely new wave of litigation separate from the gynecomastia settlement. For patients who took Risperdal and later developed breast cancer, this becomes a critical issue because they may not be covered by the 2021 settlement agreement focused on benign gynecomastia. The legal question remains unresolved: is there solid scientific evidence that Risperdal causes breast cancer, or is this correlation conflating gynecomastia with cancer risk? This distinction will be central to how courts handle these newer claims and whether they represent additional liability for J&J beyond what was settled in 2021.
The Future of Risperdal Litigation and What Remains
The remand of cases to state court in 2025 and the continued filing of new claims in 2026 indicate that Risperdal litigation is not concluded. While the 2021 settlement resolved a massive backlog of gynecomastia cases, the legal landscape continues to evolve. Future claims may focus on: (1) patients who did not know about the settlement deadline and were barred from filing, (2) breast cancer and other breast-related malignancies allegedly caused by Risperdal, and (3) additional evidence of J&J’s failure to warn or concealment of risks.
Looking forward, patients and families affected by Risperdal should understand that settlement deadlines have passed for the bulk of the 2021 agreement, but new litigation pathways continue to open. The remand to state court enables failure-to-warn claims that federal court had previously been handling, potentially creating opportunities for additional litigation. Anyone who took Risperdal and developed gynecomastia or other breast health issues should consult with experienced Risperdal attorneys promptly, as statutes of limitations and claim deadlines vary by state and type of claim.
Conclusion
The Risperdal male breast growth gynecomastia class action represents a major pharmaceutical settlement that resolved approximately 9,000 cases for $800 million following years of litigation. The case demonstrates how pharmaceutical companies can be held liable when they fail to adequately warn patients and doctors about known side effects, even when those effects are not life-threatening. From Austin Pledger’s groundbreaking 2015 verdict of $2.5 million to the broader 2021 settlement averaging $95,000 per claimant, these legal actions have provided compensation to thousands of men who suffered unexpected and often permanent breast tissue growth from Risperdal.
If you or a family member took Risperdal and developed gynecomastia, it is important to act quickly. While the main settlement has concluded, new litigation continues through state courts, and strict deadlines apply. Consult with experienced pharmaceutical litigation attorneys who can evaluate your specific situation, determine your eligibility, and advise you on remaining legal options. The landscape of Risperdal claims continues to evolve, particularly with recent allegations of breast cancer, making it essential to stay informed and pursue your claim before additional deadlines pass.